Business Context and Reporting Period
This Form 8-K filing by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) reports on events occurring on January 26, 2021. The filing details the results of a Special Meeting of Stockholders held on that date.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Corporate Actions
The primary material event reported is the approval of two proposals by stockholders:
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-15. The Board of Directors retains sole discretion to determine the specific ratio, timing, and whether to execute the split.
- Adjournment Authority: Stockholders approved the adjournment of the Special Meeting, if necessary, to solicit additional proxies should there be insufficient votes to approve the Reverse Stock Split Proposal.
Voting Results for Reverse Stock Split Proposal:
| Vote Type | Number of Votes |
|---|---|
| For | 110,449,436 |
| Against | 21,029,553 |
| Abstain | 351,060 |
Guidance, Outlook, and Management Commentary
The Board of Directors has the discretion to exercise the reverse stock split authority at any time prior to January 26, 2022 (the first anniversary of the approval). The filing states the Board will determine the specific ratio and timing based on what it deems to be in the best interest of stockholders. No financial guidance or operational outlook is provided in this filing.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once announced by the Board of Directors.
- Confirm the timing of the implementation, noting the deadline of January 26, 2022.
- Review the definitive proxy statement filed on December 17, 2020, for detailed rationale regarding the proposals.
- Monitor subsequent filings for any changes to the capital structure resulting from the authorized split.